stockrow
Friday 6 November 2026
Export CGON’s income statement to Excel — free account
CG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- Revenue
- −3.72%
- EPS
- −12.3%
- Free cash flow
- −25.2%
- Total debt
- 0.00%
Quarter to September 2026, against a year earlier
76.08
11.28
+17.41%
Follow CGON
Alert me
CG Oncology, Inc. (CGON) Revenue
CG Oncology, Inc.'s revenue for fiscal 2025 was $4.0M, up 254.7% from $1.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $6.2M. Revenue has risen for 3 consecutive fiscal years. CG Oncology, Inc. ranks 231st of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $4.0M | 254.70% |
| FY2024 | $1.1M | 458.33% |
| FY2023 | $204.0K | 6.81% |
| FY2022 | $191.0K | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $1.6M | 38.63% |
| Jun 2026 | $1.2M | 6.83% |
| Mar 2026 | $1.1M | (53.36%) |
| Dec 2025 | $2.3M | 39.38% |
| 9 more quarters | Free account |
Revenue against peers
| Company | Revenue |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | $1.2B |
| MIRM Mirum Pharmaceuticals, Inc. compare | $670.8M |
| LGND Ligand Pharmaceuticals Incorporated compare | $253.8M |
| SRRK Scholar Rock Holding Corporation compare | $47.3M |
| CGON CG Oncology, Inc. | $6.2M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| MANE Veradermics Incorporated compare | — |
| IMVT Immunovant, Inc. compare | — |
| KOD Kodiak Sciences Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on CGON
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement